Bayer Radiology Medical Affairs Department is interested in receiving and reviewing Grant Applications to support appropriate programs as described below.Therapeutic Areas/Disease States:
Intended Audience: Radiologists, MRI Technologists, Referring Physicians, MRI Nurses, Pharmacists.
Bayer Radiology Rationale for Educational Support:
Areas of interest based on referenced literature:
- Gadavist-enhanced MRI applications and protocols
- Pediatric applications and protocols for Gadavist-enhanced MRI
- Physiologic understanding of gadolinium and its properties
- Radiation and contrast dose monitoring and optimization
- Optimum protocols for power injector use in CT and MRI
- Injector use in PET
- Patient education and understanding such as breast MRI
Accredited Proposal Requirements:
The proposal must be compliant with standards and guidelines for commercial support (e.g., ACCME).
The proposal should include:
- Needs Assessment
- Educational Design and Rationale for Selection
- Learning Objectives
- Proposed Faculty
- Participant Recruitment Plan
- Outcomes Strategy/plan
- Definition of Successful Program
- Detailed Budget (must use the template available on the website)
- Copy of most recent accreditation letter and status
- Samples of other programs in similar therapeutic areas
Applications/proposals which are submitted and determined to be complete are reviewed monthly.
Acceptance of a Bayer educational grant indicates that you will:
- Reconcile grant funding within 60 days of completion of the educational program
- Permit a Bayer Medical Affairs representative to audit live programs of at least $5000 (Bayer Compliance staff may also audit live programs and/or review the use of the grant)
- Share activity data and outcomes metrics within 30 days of their availability
- Abujudeh HH, Dosaraju, VK, Kaewlai R, Acute adverse reactions to gadopentetate dimeglumine and gadobenate dimeglumine: experience with 32,659 injections, AJR AM J Roentgenol. 2010 Feb; 194(2); 430-434.
- Altun E, Martin DR, Wertman R, et al. Nephrogenic systemic fibrosis: change in incidence following a switch in gadolinium agents and adoption of a gadolinium policy-report from two US universities. Radiology. 2009 Dec; 253(3):689-696. Epub 2009 Sept 29.
- Bellin MF, Van Der Molen AJ. Extracellular gadolinium-based contrast media: an overview. Eur J Radiol. 2008 May; 66(2):160-167. Epub 2008 Mar20.Review.
- Forsting M, Palkowitsch P. Prevalence of acute adverse reactions to gadobutrol-a highly concentrated macrocyclic gadolinium chelate: review of 14,299 patients from observational trials. Eur J Radiol. 2010 Jun; 74(3):e186-192. Epub 2009 Jul2.
- Ge Y, Multiple sclerosis: the role of MR imaging, AJNR Am J Neuroradiol, 2006; 27: 1165-76.
- Kurtkoti, J., et al. Gadolinium and Nephrogenic Systemic Fibrosis: Association or Causation, Nephrology June 2008;13: 235-41.
- Lin SP, Brown JJ. MR contrast agents. Physical and pharmacologic basics. J Magn Reson Imaging. 2007; 25:884-899 Abstract.
- Morcos SK. Extracellular gadolinium contrast agents: difference in stability. Eur J Radiol. 2008 May;66(2): 175-179. Epub 2008 Mar14.
- Provenzale JM, Mukundan S, Barboriak DP. Diffusion-weighted and perfusion MR imaging for brain tumor characterization and assessment of treatment response. Radiology. 2006 Jun;239(3):632-49. (2006) Abstract.
- ACR Practice Guideline for Performing and Interpreting Magnetic Resonance Imaging (MRI)., Available at the American College of Radiology web site: